CR10583A - Derivados de 1-(-d glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio - Google Patents

Derivados de 1-(-d glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio

Info

Publication number: CR10583A
Authority: CR; Costa Rica
Prior art keywords: cyclopropylpenhylmethyl; glucopiranosil; indol; conveyors; inhibitors
Prior art date: 2006-07-27

Application number

CR10583A

Other languages

English (en)

Inventor

Nomura Sumihiro

Sakamaki Shigeki

Original Assignee

Mitsubishi Tanabe Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-07-27

Filing date

2009-01-26

Publication date

2009-06-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38515468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10583(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-01-26 Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp

2009-06-05 Publication of CR10583A publication Critical patent/CR10583A/es

Links

WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title 1
239000008103 glucose Substances 0.000 title 1
229910052736 halogen Inorganic materials 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Genetics & Genomics (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

CR10583A 2006-07-27 2009-01-26 Derivados de 1-(-d glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio CR10583A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82060406P	2006-07-27	2006-07-27
US88617807P	2007-01-23	2007-01-23

Publications (1)

Publication Number	Publication Date
CR10583A true CR10583A (es)	2009-06-05

Family

ID=38515468

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR10583A CR10583A (es)	2006-07-27	2009-01-26	Derivados de 1-(-d glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio

Country Status (31)

Country	Link
US (1)	US7851617B2 (es)
EP (1)	EP2049557B1 (es)
JP (1)	JP5102294B2 (es)
KR (1)	KR101179312B1 (es)
CN (1)	CN101501053B (es)
AR (1)	AR062111A1 (es)
AT (1)	ATE501159T1 (es)
AU (1)	AU2007277662B2 (es)
BR (1)	BRPI0715369A2 (es)
CA (1)	CA2658116C (es)
CL (1)	CL2007002197A1 (es)
CO (1)	CO6150170A2 (es)
CR (1)	CR10583A (es)
DE (1)	DE602007013056D1 (es)
DK (1)	DK2049557T3 (es)
EA (1)	EA016819B1 (es)
GT (1)	GT200900014A (es)
HN (1)	HN2009000161A (es)
IL (1)	IL196267A0 (es)
JO (1)	JO2681B1 (es)
MX (1)	MX2009000995A (es)
MY (1)	MY145106A (es)
NO (1)	NO20085337L (es)
NZ (1)	NZ574072A (es)
PE (1)	PE20080522A1 (es)
PL (1)	PL2049557T3 (es)
PT (1)	PT2049557E (es)
TW (1)	TWI418556B (es)
UA (1)	UA92100C2 (es)
UY (1)	UY30506A1 (es)
WO (1)	WO2008013322A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008070609A1 (en) *	2006-12-04	2008-06-12	Janssen Pharmaceutica N.V.	Thienyl-containing glycopyranosyl derivatives as antidiabetics
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
NZ600110A (en)	2007-09-10	2013-03-28	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of sglt
CL2008003653A1 (es)	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
WO2009117421A2 (en) *	2008-03-17	2009-09-24	Kalypsys, Inc.	Heterocyclic modulators of gpr119 for treatment of disease
AP2728A (en)	2008-08-28	2013-08-31	Pfizer	Dioxa-bicyclo[3.2.1.] octane-2,3,4-triol derivatives
US9056850B2 (en) *	2008-10-17	2015-06-16	Janssen Pharmaceutica N.V.	Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en)	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
US8772512B2 (en)	2009-07-10	2014-07-08	Janssen Pharmaceutica Nv	Crystallisation process for 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene
IN2012DN02711A (es)	2009-09-15	2015-09-11	Janssen Pharmaceutica Nv
PH12012500698A1 (en) *	2009-10-14	2016-05-27	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of sglt2
WO2011048148A2 (en)	2009-10-20	2011-04-28	Novartis Ag	Glycoside derivative and uses thereof
DK2496583T3 (en)	2009-11-02	2015-02-02	Pfizer	Dioxa-bicyclo [3.2.1] octane-2,3,4-triol DERIVATIVES
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
ES2596291T3 (es)	2010-05-11	2017-01-05	Janssen Pharmaceutica, N.V.	Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
FR2969614A1 (fr) *	2010-12-28	2012-06-29	Sanofi Aventis	Nouveaux derives de pyrimidinones, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
SI2658844T1 (sl)	2010-12-28	2017-02-28	Sanofi	Novi derivati pirimidina, njihova priprava in njihova farmacevtska uporaba kot inhibitorje AKT(PKB) fosforilacije
CN103596944B (zh)	2011-04-13	2017-02-22	詹森药业有限公司	可用作sglt2的抑制剂的化合物的制备方法
US9035044B2 (en)	2011-05-09	2015-05-19	Janssen Pharmaceutica Nv	L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
WO2012162115A2 (en) *	2011-05-20	2012-11-29	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of sglt-2
WO2012162113A1 (en) *	2011-05-20	2012-11-29	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibittors of sglt-2
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en)	2011-09-27	2013-04-04	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201335176A (zh) *	2011-12-15	2013-09-01	Nat Health Research Institutes	新穎醣苷化合物
AR097890A1 (es)	2013-10-17	2016-04-20	Lilly Co Eli	Compuestos de urea
AR098134A1 (es)	2013-11-01	2016-05-04	Lilly Co Eli	Compuestos de urea
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
JP7137318B2 (ja) *	2018-02-22	2022-09-14	オルガノ株式会社	被処理液の精製方法
CN115772163B (zh) *	2022-12-09	2025-07-22	中国科学院成都生物研究所	吲哚糖苷类化合物及吡咯糖苷类化合物及合成方法与应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2102591C (en) *	1992-11-12	2000-12-26	Kenji Tsujihara	Hypoglycemic agent
US5731292A (en) *	1992-11-12	1998-03-24	Tanabe Seiyaku Co., Ltd.	Dihydrochalcone derivatives which are hypoglycemic agents
US5830873A (en) *	1994-05-11	1998-11-03	Tanabe Seiyaku Co., Ltd.	Propiophenone derivative and a process for preparing the same
US6515117B2 (en) *	1999-10-12	2003-02-04	Bristol-Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en)	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
US6627611B2 (en) *	2000-02-02	2003-09-30	Kotobuki Pharmaceutical Co Ltd	C-glycosides and preparation of thereof as antidiabetic agents
JP4456768B2 (ja)	2000-02-02	2010-04-28	壽製薬株式会社	Ｃ−配糖体を含有する薬剤
CZ20023023A3 (cs)	2000-03-17	2003-04-16	Kissei Pharmaceutical Co., Ltd.	Glukopyranosyloxybenzylbenzenové deriváty, léčivé směsi obsahující tyto látky a meziprodukty pro přípravu derivátů
US6683056B2 (en)	2000-03-30	2004-01-27	Bristol-Myers Squibb Company	O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en)	2000-03-30	2003-04-29	Bristol-Myers Squibb Company	O-glucosylated benzamide SGLT2 inhibitors and method
MXPA03005923A (es) *	2000-12-28	2004-01-26	Kissei Pharmaceuticals Co Ltd	Derivados de glupopiranosiloxipirazol y su uso en medicinas.
WO2002068439A1 (fr)	2001-02-26	2002-09-06	Kissei Pharmaceutical Co., Ltd.	Derives de glycopyranosyloxypyrazole et utilisation medicinale de ceux-ci
US7294618B2 (en) *	2001-02-27	2007-11-13	Kissei Pharmaceutical Co., Ltd.	Glucopyranosyloxypyrazole derivatives and medicinal use thereof
US6936590B2 (en) *	2001-03-13	2005-08-30	Bristol Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
ATE318272T1 (de)	2001-04-11	2006-03-15	Bristol Myers Squibb Co	Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
JP4292570B2 (ja) *	2001-04-27	2009-07-08	味の素株式会社	Ｎ−置換ピラゾール−ｏ−グリコシド誘導体及びそれらを含有する糖尿病治療薬
JP4115105B2 (ja)	2001-07-02	2008-07-09	協和醗酵工業株式会社	ピラゾール誘導体
WO2003011880A1 (fr)	2001-07-31	2003-02-13	Kissei Pharmaceutical Co., Ltd.	Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
US20030087843A1 (en) *	2001-09-05	2003-05-08	Washburn William N.	O-pyrazole glucoside SGLT2 inhibitors and method of use
US6562791B1 (en) *	2002-03-29	2003-05-13	Council Of Scientific And Industrial Research	Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
DE10231370B4 (de) *	2002-07-11	2006-04-06	Sanofi-Aventis Deutschland Gmbh	Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en)	2002-08-05	2006-05-11	Yamanouchi Pharma Co Ltd	Azulene derivative and salt thereof
UA77300C2 (en)	2002-08-09	2006-11-15	Taisho Pharmaceutical Co Ltd	5-thio-?-d-glucopyranoside derivatives and pharmaceutical composition for treating diabetes
AU2003262262A1 (en)	2002-08-27	2004-03-19	Kissei Pharmaceutical Co., Ltd.	Pyrazole derivatives, medicinal composition containing the same, and medicinal use thereof
DE10258008B4 (de)	2002-12-12	2006-02-02	Sanofi-Aventis Deutschland Gmbh	Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de)	2002-12-12	2006-02-09	Sanofi-Aventis Deutschland Gmbh	Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
PL1609785T3 (pl)	2003-03-14	2016-07-29	Astellas Pharma Inc	Pochodne c-glikozydowe i ich sole
WO2005012326A1 (en) *	2003-08-01	2005-02-10	Tanabe Seiyaku Co., Ltd.	Novel compounds having inhibitory activity against sodium-dependant transporter
RS20060320A (sr) *	2003-08-01	2008-08-07	Janssen Pharmaceutica N.V.,	Supstituisani indazol-o-glukozidi
SG130189A1 (en) *	2003-08-01	2007-03-20	Janssen Pharmaceutica Nv	Substituted indole-o-glucosides
EP1679965A4 (en) *	2003-08-01	2009-05-27	Janssen Pharmaceutica Nv	SUBSTITUTED ANELLIERED HETEROCYCLIC C-GLYCOSIDES
UA86042C2 (en) *	2003-08-01	2009-03-25	Янссен Фармацевтика Н.В.	Substituted indazole-o-glucosides
EA011515B1 (ru) *	2003-08-01	2009-04-28	Янссен Фармацевтика Н.В.	Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
CA2581922A1 (en)	2004-09-29	2006-04-06	Kissei Pharmaceutical Co., Ltd.	1-(.beta.-d-glycopyranosyl)-3-substituted nitrogenous heterocyclic compound, medicinal composition containing the same, and medicinal use thereof
AR053329A1 (es) *	2005-01-31	2007-05-02	Tanabe Seiyaku Co	Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
JP2008050353A (ja) *	2006-07-27	2008-03-06	Mitsubishi Tanabe Pharma Corp	医薬組成物

2007
- 2007-07-11 TW TW096125166A patent/TWI418556B/zh not_active IP Right Cessation
- 2007-07-25 JO JO2007306A patent/JO2681B1/en active
- 2007-07-25 UY UY30506A patent/UY30506A1/es unknown
- 2007-07-26 PE PE2007000981A patent/PE20080522A1/es not_active Application Discontinuation
- 2007-07-26 US US11/878,760 patent/US7851617B2/en not_active Expired - Fee Related
- 2007-07-26 CL CL200702197A patent/CL2007002197A1/es unknown
- 2007-07-26 AR ARP070103316A patent/AR062111A1/es unknown
- 2007-07-27 MY MYPI20090277A patent/MY145106A/en unknown
- 2007-07-27 PL PL07791887T patent/PL2049557T3/pl unknown
- 2007-07-27 NZ NZ574072A patent/NZ574072A/en not_active IP Right Cessation
- 2007-07-27 CN CN2007800277313A patent/CN101501053B/zh not_active Expired - Fee Related
- 2007-07-27 BR BRPI0715369-4A patent/BRPI0715369A2/pt not_active IP Right Cessation
- 2007-07-27 DE DE602007013056T patent/DE602007013056D1/de active Active
- 2007-07-27 DK DK07791887.8T patent/DK2049557T3/da active
- 2007-07-27 PT PT07791887T patent/PT2049557E/pt unknown
- 2007-07-27 AT AT07791887T patent/ATE501159T1/de active
- 2007-07-27 MX MX2009000995A patent/MX2009000995A/es active IP Right Grant
- 2007-07-27 KR KR1020097004110A patent/KR101179312B1/ko not_active Expired - Fee Related
- 2007-07-27 AU AU2007277662A patent/AU2007277662B2/en not_active Ceased
- 2007-07-27 JP JP2009521499A patent/JP5102294B2/ja not_active Expired - Fee Related
- 2007-07-27 UA UAA200901760A patent/UA92100C2/uk unknown
- 2007-07-27 WO PCT/JP2007/065213 patent/WO2008013322A1/en not_active Ceased
- 2007-07-27 EP EP07791887A patent/EP2049557B1/en active Active
- 2007-07-27 EA EA200970161A patent/EA016819B1/ru not_active IP Right Cessation
- 2007-07-27 CA CA2658116A patent/CA2658116C/en not_active Expired - Fee Related
2008
- 2008-12-19 NO NO20085337A patent/NO20085337L/no not_active Application Discontinuation
- 2008-12-30 IL IL196267A patent/IL196267A0/en not_active IP Right Cessation
2009
- 2009-01-22 GT GT200900014A patent/GT200900014A/es unknown
- 2009-01-26 HN HN2009000161A patent/HN2009000161A/es unknown
- 2009-01-26 CR CR10583A patent/CR10583A/es unknown
- 2009-01-27 CO CO09006937A patent/CO6150170A2/es unknown

Also Published As

Publication number	Publication date
TW200811149A (en)	2008-03-01
JO2681B1 (en)	2013-03-03
CN101501053A (zh)	2009-08-05
ATE501159T1 (de)	2011-03-15
US7851617B2 (en)	2010-12-14
HN2009000161A (es)	2011-05-25
MX2009000995A (es)	2009-02-04
DE602007013056D1 (de)	2011-04-21
MY145106A (en)	2011-12-30
CN101501053B (zh)	2012-10-03
JP5102294B2 (ja)	2012-12-19
US20080027122A1 (en)	2008-01-31
UY30506A1 (es)	2008-01-31
CA2658116A1 (en)	2008-01-31
GT200900014A (es)	2010-02-09
EP2049557B1 (en)	2011-03-09
NO20085337L (no)	2009-04-24
PE20080522A1 (es)	2008-06-13
BRPI0715369A2 (pt)	2013-06-18
AR062111A1 (es)	2008-10-15
AU2007277662B2 (en)	2011-02-03
KR101179312B1 (ko)	2012-09-03
PT2049557E (pt)	2011-05-05
CL2007002197A1 (es)	2008-02-15
CO6150170A2 (es)	2010-04-20
EP2049557A1 (en)	2009-04-22
WO2008013322A1 (en)	2008-01-31
NZ574072A (en)	2011-05-27
UA92100C2 (uk)	2010-09-27
AU2007277662A1 (en)	2008-01-31
JP2009544693A (ja)	2009-12-17
EA200970161A1 (ru)	2009-06-30
IL196267A0 (en)	2009-09-22
KR20090040356A (ko)	2009-04-23
EA016819B1 (ru)	2012-07-30
CA2658116C (en)	2011-07-19
DK2049557T3 (da)	2011-06-14
TWI418556B (zh)	2013-12-11
PL2049557T3 (pl)	2011-07-29

Publication	Publication Date	Title
CR10583A (es)	2009-06-05	Derivados de 1-(-d glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio
CR10743A (es)	2009-06-05	Derivados de azaadamantano y metodos de uso de los mismos
BRPI0810524A2 (pt)	2014-10-21	Derivado de (aza)indol e uso do mesmo para propósitos médicos
BRPI0810522A2 (pt)	2014-10-21	Mimétricos diazo bicíclicos de smac e uso dos mesmos.
BRPI0720625A2 (pt)	2014-03-25	Derivados de indol de 4,5-anel anulados e métodos de uso dos mesmos
CY1120741T1 (el)	2019-12-11	Θεραπεια οζωδους σκληρυνσης
MA28824B1 (fr)	2007-08-01	Derives de pyrimidine
ATE415400T1 (de)	2008-12-15	Pyrazolopyridinderivate
FR20C1027I2 (fr)	2021-06-11	Derives de tiglien-3-one
BRPI0809346A2 (pt)	2014-10-07	Compostos derivados substituídos de imidazopiridina e composição farmacêutica contendo os mesmos
BRPI0815811A2 (pt)	2015-02-18	Derivados de indol substituído e métodos de uso dos mesmos
MA28813B1 (fr)	2007-08-01	Derives de pyrimidine
BRPI0720124A2 (pt)	2014-03-04	Composições farmacêuticas e seus métodos de uso.
EP4125244C0 (en)	2025-01-01	HASH BASED MULTIHOSTING
DE602005026867D1 (de)	2011-04-21	Entzündungshemmende indol-derivate
EP1731506A4 (en)	2009-12-09	5-HYDROXYINDOL-3-CARBOXYLATE DERIVATIVES AND THEIR USE
BRPI0813457A2 (pt)	2014-12-23	Composto de organoenxofre contendo halogênio e uso do mesmo
BRPI0812909A2 (pt)	2014-12-09	Derivados de guanina policíclica e métodos de uso dos mesmos.
DK2069310T3 (da)	2012-03-19	Sulfonylpyrazolin-1-carboxamidin-derivater som 5-HT6-antagonister
BRPI0808172A2 (pt)	2014-11-04	Compostos heterocíclicos, composições compreendendo-os e métodos de seu uso.
DK1763517T3 (da)	2011-06-06	Pyrimidinderivater som 11beta-HSD1-inhibitorer
DK1957492T3 (da)	2011-02-28	Substituerede bicykliske pyrimidonderivater
BRPI0815373A2 (pt)	2015-02-10	Derivados de ciclo-hexeno e o uso dos mesmos como fragrâncias
DE602006010581D1 (de)	2009-12-31	4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
DK1740583T3 (da)	2009-10-19	Oxadiazolon-derivater som ppar-delta-agonister